Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 3/20 | 0.51 |
| ▸ | CDK4 | P11802 | 2/20 | 0.51 |
| ▸ | CCND1 | P24385 | 2/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073911 | 0.90 | CDK2 (0.54) | SYKALKCDK2CDK4CCND1 | |
| SCHEMBL6073486 | 0.88 | CDK4 (0.50) | SYKCDK2CDK4CCND1CCNE1 | |
| SCHEMBL6074378 | 0.87 | SYK (0.56) | SYKALKCDK2CDK4CCND1 | |
| SCHEMBL6073849 | 0.87 | EGFR (0.53) | SYKALKJAK3 | |
| SCHEMBL6073515 | 0.86 | CDK4 (0.54) | SYKALKCDK2CDK4CCND1 | |
| SCHEMBL6073406 | 0.86 | ALK (0.54) | SYKALKCDK2CDK4CCND1 | |
| SCHEMBL6074079 | 0.84 | SYK (0.55) | SYKALKJAK2BRD4 | |
| SCHEMBL6074659 | 0.84 | SYK (0.58) | SYKALKCDK2CDK4CCND1 | |
| SCHEMBL6073815 | 0.83 | CDK4 (0.45) | SYKCDK2CDK4CCND1JAK3 | |
| SCHEMBL6073811 | 0.83 | CDK4 (0.45) | SYKCDK2CDK4CCND1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | claimed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | claimed |
| EP-1254137-A1 | PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | claimed |
| WO-2001055147-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | SYK 1176/4885ALK 457/4885CDK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.